Search | Clinical Trials Finder

Conditions: Anthrax
Interventions: PA83-FhCMB; Biological
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV Infections
Interventions: MPER-656 Liposome Vaccine, Placebo for MPER-656 Liposome Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Plasmodium Falciparum Malaria
Interventions: Malaria ICC-1132, Alhydrogel; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 4
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: HIV Infection, Hepatitis B
Interventions: HEPLISAV-B, ENGERIX-B; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Skin Diseases, Infectious
Interventions: Trimethoprim-sulfamethoxazole, Placebo group; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer, HIV Vaccine
Interventions: Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Redwood City, California

Conditions: COVID-19
Interventions: Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 65 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more

Conditions: Zika Virus Infection
Interventions: IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Mosquito-Borne Infectious Diseases
Interventions: AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lyme Borreliosis, Nervous System
Interventions: VLA15 with Alum, VLA15 without Alum; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: La Mesa, California • Lincoln, Nebraska

Conditions: Hepatitis E, Immunisation
Interventions: HEV 239, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 3,258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 47
States / cities: Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more

Conditions: Dyspepsia, GERD, Acid Reflux
Interventions: Intravenous Famotidine, Oral Maalox/ Mylanta; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Zika Virus Infection
Interventions: Saline, Zika Virus Purified Inactivated Vaccine (ZPIV); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Respiratory Tract Infection
Interventions: RSV vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 145
States / cities: Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more

Conditions: HIV Infections
Interventions: EnvDNA, PolyEnv1, EnvPro; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Stanford, California • Torrance, California • Baltimore, Maryland + 2 more

Search by objective public record fields.

PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Safety Study of Hepatitis E Vaccine (HEV239)

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Famotidine and Antacids for Treatment of Dyspepsia

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

ZIKA Vaccine in Naive Subjects

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults